Loading...
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
IMPORTANCE: Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. OBJECTIVE: To assess the efficacy and safety of avelumab, an anti–programmed death-ligand 1 agent, in a cohort of...
Na minha lista:
| Udgivet i: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Medical Association
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439837/ https://ncbi.nlm.nih.gov/pubmed/30676622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.6258 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|